155 related articles for article (PubMed ID: 34675468)
1. Twenty-Four-Hour Intraocular Pressure Control with Omidenepag Isopropyl 0.002% in Patients with Glaucoma and Ocular Hypertension.
Shiratori N; Nishio Y; Takeda A; Sugimoto S; Takazawa K; Otsuka N; Ishida N; Shii D; Hori K; Nakamoto K
Clin Ophthalmol; 2021; 15():3997-4003. PubMed ID: 34675468
[TBL] [Abstract][Full Text] [Related]
2. Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study.
Aihara M; Ropo A; Lu F; Kawata H; Iwata A; Odani-Kawabata N; Shams N
Jpn J Ophthalmol; 2020 Jul; 64(4):398-406. PubMed ID: 32572719
[TBL] [Abstract][Full Text] [Related]
3. Human experience and efficacy of omidenepag isopropyl (Eybelis®; Omlonti®): Discovery to approval of the novel non-prostaglandin EP2-receptor-selective agonist ocular hypotensive drug.
Sharif NA
Curr Opin Pharmacol; 2024 Feb; 74():102426. PubMed ID: 38168596
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Omidenepag Isopropyl 0.002% Ophthalmic Solution: A Retrospective Analysis of Real-World Data in Japan.
Miki A; Miyamoto E; Ishida N; Shii D; Hori K;
Adv Ther; 2022 May; 39(5):2085-2095. PubMed ID: 35287233
[TBL] [Abstract][Full Text] [Related]
5. Twelve-month efficacy and safety of omidenepag isopropyl, a selective EP2 agonist, in open-angle glaucoma and ocular hypertension: the RENGE study.
Aihara M; Lu F; Kawata H; Iwata A; Odani-Kawabata N
Jpn J Ophthalmol; 2021 Nov; 65(6):810-819. PubMed ID: 34495425
[TBL] [Abstract][Full Text] [Related]
6. Omidenepag Isopropyl Versus Latanoprost in Primary Open-Angle Glaucoma and Ocular Hypertension: The Phase 3 AYAME Study.
Aihara M; Lu F; Kawata H; Iwata A; Odani-Kawabata N; Shams NK
Am J Ophthalmol; 2020 Dec; 220():53-63. PubMed ID: 32533949
[TBL] [Abstract][Full Text] [Related]
7. Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension.
Aihara M; Lu F; Kawata H; Iwata A; Liu K; Odani-Kawabata N; Shams NK
J Glaucoma; 2019 May; 28(5):375-385. PubMed ID: 30839416
[TBL] [Abstract][Full Text] [Related]
8. Single Administration of Bimatoprost Implant: Effects on 24-Hour Intraocular Pressure and 1-Year Outcomes.
Weinreb RN; Christie WC; Medeiros FA; Craven ER; Kim K; Nguyen A; Bejanian M; Wirta DL
Ophthalmol Glaucoma; 2023; 6(6):599-608. PubMed ID: 37343625
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Patient Tolerability of Omidenepag Isopropyl in the Treatment of Glaucoma and Ocular Hypertension.
Matsuo M; Matsuoka Y; Tanito M
Clin Ophthalmol; 2022; 16():1261-1279. PubMed ID: 35510270
[TBL] [Abstract][Full Text] [Related]
10. Interim Results of Post-Marketing Observational Study of Omidenepag Isopropyl for Glaucoma and Ocular Hypertension in Japan.
Nakazawa T; Takahashi K; Kuwayama Y; Nomura A; Shimada F
Adv Ther; 2022 Mar; 39(3):1359-1374. PubMed ID: 35072890
[TBL] [Abstract][Full Text] [Related]
11. Newly or switching effect of a selective EP2 agonist on intraocular pressure in Japanese patients with open-angle glaucoma.
Ueda K; Sakata R; Fujishiro T; Honjo M; Shirato S; Aihara M
Jpn J Ophthalmol; 2022 Sep; 66(5):434-439. PubMed ID: 35906503
[TBL] [Abstract][Full Text] [Related]
12. 24-Hour Intraocular Pressure Control with Fixed-dose Combination Brinzolamide 1%/Brimonidine 0.2%: A Multicenter, Randomized Trial.
Weinreb RN; Bacharach J; Fechtner RD; Kahook MY; Wirta D; Burmaster S; Meng X; Hubatsch DA
Ophthalmology; 2019 Aug; 126(8):1095-1104. PubMed ID: 30403988
[TBL] [Abstract][Full Text] [Related]
13. Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive Monkeys.
Fuwa M; Shimazaki A; Odani-Kawabata N; Kirihara T; Taniguchi T; Iwamura R; Yoneda K; Kato M; Morishima K; Shams NK
J Ocul Pharmacol Ther; 2021 May; 37(4):223-229. PubMed ID: 33600237
[No Abstract] [Full Text] [Related]
14. Clinical Efficacy of Omidenepag Isopropyl for Primary Open-Angle Glaucoma, Normal Tension Glaucoma, or Ocular Hypertension: A Meta-Analysis.
Kuo HT; Yeh CY; Hsu AY; Ho JH; Lin CJ; Tsai YY
J Ocul Pharmacol Ther; 2023 Dec; 39(10):705-715. PubMed ID: 37579061
[No Abstract] [Full Text] [Related]
15. Pharmacokinetics, Safety, and Intraocular Pressure-Lowering Profile of Omidenepag Isopropyl, a Selective, Nonprostaglandin, Prostanoid EP2 Receptor Agonist, in Healthy Japanese and Caucasian Volunteers (Phase I Study).
Aihara M; Lu F; Kawata H; Tanaka Y; Yamamura K; Odani-Kawabata N; Shams NK
J Ocul Pharmacol Ther; 2019 Dec; 35(10):542-550. PubMed ID: 31674861
[No Abstract] [Full Text] [Related]
16. A Randomized, Phase 2 Study of 24-h Efficacy and Tolerability of Netarsudil in Ocular Hypertension and Open-Angle Glaucoma.
Peace JH; McKee HJ; Kopczynski CC
Ophthalmol Ther; 2021 Mar; 10(1):89-100. PubMed ID: 33244711
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic Characterization of Omidenepag Isopropyl, a Novel Selective EP2 Receptor Agonist, as an Ocular Hypotensive Agent.
Kirihara T; Taniguchi T; Yamamura K; Iwamura R; Yoneda K; Odani-Kawabata N; Shimazaki A; Matsugi T; Shams N; Zhang JZ
Invest Ophthalmol Vis Sci; 2018 Jan; 59(1):145-153. PubMed ID: 29332128
[TBL] [Abstract][Full Text] [Related]
18. The 24-hour intraocular pressure control by tafluprost/timolol fixed combination after switching from the concomitant use of tafluprost and timolol gel-forming solution, in patients with primary open-angle glaucoma.
Nakamoto K; Takeshi M; Hiraoka T; Eguchi M; Nakano Y; Otsuka N; Hizaki H; Akai H; Hashimoto M
Clin Ophthalmol; 2018; 12():359-367. PubMed ID: 29497276
[TBL] [Abstract][Full Text] [Related]
19. The diurnal and nocturnal effect of travoprost with sofZia on intraocular pressure and ocular perfusion pressure.
Seibold LK; Kahook MY
Am J Ophthalmol; 2014 Jan; 157(1):44-49.e1. PubMed ID: 24182742
[TBL] [Abstract][Full Text] [Related]
20. Twenty-four-hour efficacy of preservative-free tafluprost for open-angle glaucoma patients, assessed by home intraocular pressure (Icare-ONE) and blood-pressure monitoring.
Cho SY; Kim YY; Yoo C; Lee TE
Jpn J Ophthalmol; 2016 Jan; 60(1):27-34. PubMed ID: 26411460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
